IL-12-and IL-23 in health and disease

Croxford, Andrew L.; Kulig, Paulina; Becher, Burkhard

doi:10.1016/j.cytogfr.2014.07.017

Cited by 130 publications

(113 citation statements)

References 110 publications

(120 reference statements)

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…First,IL-12 can stimulate the synthesis and secretion of IFN-γ, which serves as a pro-inflammatory and tumor-suppressive factor (Croxford, et al,2014). In addition, it was found that p53, which triggers apoptosis in cancer cells, was up-regulated with the secretion of IFN-γ, thus, subsequently,inhibiting tumor growth (Takaoka, et al,2003).…”

Section: Discussionmentioning

confidence: 99%

“…As mentioned above, the IL-12 p35 and IL-12 p40 subunitsare encoded by the IL-12A and IL-12B genes, respectively (Croxford, et al,2014). Consequently, IL-12A and IL-12B genetic polymorphisms, which may affect the expression levels and normal functioning of IL-12, are thought to be implicated in the occurrence and development of various types of cancer (Yuzhalin and Kutikhin,2012).…”

Section: Discussionmentioning

confidence: 99%

“…Biologically active IL-12 consists of two functional subunits (p35 and p40), which are encoded by the IL-12A and IL-12B genes, respectively (Croxford, et al,2014). Since the tumor-suppressive effect of IL-12 is well documented, functional polymorphisms of the IL-12A and IL-12B genes are thought to be good genetic candidates for cancer susceptibility.…”

Section: Introductionmentioning

confidence: 99%

“…IL-12 targets T-helper (Th) cells and natural killer (NK) cells, and stimulates the synthesis and secretion of interferon gamma (IFN-γ), which is a well-established anti-tumor factor (Croxford, et al,2014). Additionally, lower serum IL-12 levelshave been observed in patients with various types of cancer (Green, et al,2012;Stanilov, et al,2012;Tao, et al,2012;Wang, et al,2013;Fang, et al,2015), suggesting that IL-12 might function as a potent tumor-suppressive factor.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Single-nucleotide polymorphisms of the IL-12 gene lead to a higher cancer risk: a meta-analysis based on 22,670 subjects

et al. 2017

View full text Add to dashboard Cite

The associations between interleukin-12 (IL-12) gene polymorphisms and cancer risk have been discussed extensively, with controversial results. Therefore, we conducted the present meta-analysis to better assess the potential roles of IL-12 gene variation in cancer occurrence. Eligible articles were found via PubMed, Medline, EMBASE, Google Scholar and CNKI. Odds ratios and 95% confidence intervals were used to evaluate the associations between IL-12 gene polymorphisms and cancer risk.Thirty-one studies with 10,749 cancer patients and 11,921 healthy subjects were included in the analyses. The overall results showed that cancer risk was increased by IL-12A rs568408 (GG versus GA + AA: P = 0.004; G versus A: P = 0.005) and IL-12B rs3212227 (AA versus AC + CC: P = 0.004; CC versus AA + AC: P = 0.03; A versus C: P = 0.007) polymorphisms. Further subgroup analyses for IL-12A rs568408 and IL-12B rs3212227 revealed that the positive results could be impacted by the ethnicity of the population, cancer type and/or genotyping methods. However, we failed to detect any significant associations between theIL-12A rs2243115 polymorphism and cancer risk in either the overall or the subgroup analyses. The current study suggests that certain IL-12 gene polymorphisms serve as biological 3 markers of cancer susceptibility.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Single-nucleotide polymorphisms of the IL-12 gene lead to a higher cancer risk: a meta-analysis based on 22,670 subjects

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Physiologically, IL-23 is produced by antigen presenting cells (APC) and promotes the expansion and survival of Th17 cells, but has no role in the differentiation of the lineage. In pathologic situation IL-23 is strongly associated to autoimmune diseases and chronic inflammation [13][14][15][16], in particular its involvement in Psoriasis [17], Miastenia Gravis [18], Rheumatoid Arthritis [19] and inflammatory bowel disease [20][21][22] has been described. Currently, the study of the combination IL-23, IL-12/Th17 as a therapeutic target is of great interest as demonstrated by the various antibodies recently subjected to clinical studies [14].…”

Section: Introductionmentioning

confidence: 99%

Generation of a Chimeric Antibody against a Synthetic Peptide Derived From IL-23p19 with Potential Therapeutic Application

Pérez-Etcheverry

Carmen

2017

IRA-JAS

View full text Add to dashboard Cite

Aim: To construct an express a mouse-human chimeric antibody against IL-23p19 using a synthetic peptide as immunogen.Methods: Immunization of mice with a synthetic peptide derived from the IL-23p19 sequence and generation of hybridoma secreting specific antibodies. The chimeric antibody was created using two eukaryotic plasmid constructions; one of them carrying the light mouse-human chain and the other the heavy mouse-human chain. CHO-K1 cells were cotransfected with both plasmids and stable transfectants were grown in selective culture medium.Results: A chimeric version of anti-IL-23p19 was successfully constructed and expressed in eukaryotic cells. The expressed chimeric antibody showed specific recognition not only of the peptide used as immunogen but also the subunit p19 and the complete interleukin Il-23.Conclusion: A Chimeric antibody that was developed against a synthetic peptide, which is able to recognize the parent protein IL23 biologically active, could be developed into a targeted therapy in diseases with chronic inflammation.

show abstract

Inflammation and Cancer

Todoric,

Umemura,

Taniguchi

et al. 2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Epidemiological studies and experimental evidence have provided strong support to the long standing notion that chronic inflammation stimulates the development and progression of malignant neoplasms. It is now clear that pre‐existing inflammation caused by persistent viral and microbial infections, autoimmune diseases, environmental irritants, and even obesity promote tumor development and may account for up to 20% of all cancer deaths. Inflammation also appears subsequent to cancer development and such “tumor‐elicited inflammation” plays a key role in the malignant progression and metastatic dissemination of most cancers. Although some common anti‐inflammatory drugs, such as aspirin, substantially reduce cancer risk, there is still an unmet need for the clinical development of new therapeutics that target cancer‐associated inflammation.

show abstract

IL-12-and IL-23 in health and disease

Cited by 130 publications

References 110 publications

Single-nucleotide polymorphisms of the <i>IL-12</i> gene lead to a higher cancer risk: a meta-analysis based on 22,670 subjects

Single-nucleotide polymorphisms of the <i>IL-12</i> gene lead to a higher cancer risk: a meta-analysis based on 22,670 subjects

Generation of a Chimeric Antibody against a Synthetic Peptide Derived From IL-23p19 with Potential Therapeutic Application

Inflammation and Cancer

Contact Info

Product

Resources

About